fbpx

Drug Duo Extends Survival for Some Advanced Breast Cancer Patients

Pharmaceutical giant Pfizer has recently announced the results of their PALOMA-3 trial which evaluated Ibrance (palbociclib) in combination with Fulvestrant (Faslodex) in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease progressed on or after prior endocrine therapy. The combination of drugs showed improved therapy performance in [...]

Pharmaceutical giant Pfizer has recently announced the results of their PALOMA-3 trial which evaluated Ibrance (palbociclib) in combination with Fulvestrant (Faslodex) in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease progressed on or after prior endocrine therapy. The combination of drugs showed improved therapy performance in almost every aspect.

The study began in 2016 and gathered 521 participants. Patients were administered 125mg daily doses of palbociclib for 21 consecutive days, then a week off, and 500mg fulvestrant injections every two weeks. At the end of the program, a significant progression could be detected. The median overall survival (OS) rate was 34.9 months, compared to previous 28.0 months. Among cases with documented sensitivity to previous endocrine therapies, the median OS difference was even more noticeable, 39.7 months, compared to 29.7 months.

It’s noteworthy that the magnitude of progression-free survival benefit observed in PALOMA-3 has translated to a similar difference of nearly seven months in overall survival, which is clinically meaningful”, said Massimo Cristofanilli, M.D.,  senior investigator of the PALOMA-3 trial.

Another positive development was the prolonged time between randomization to first use of chemotherapy post-progression. This also increased from 8.8 months to 17.6 months.

Delaying the need for chemotherapy is a central goal of treatment for women with this disease. These new data from PALOMA-3 show that adding IBRANCE to fulvestrant led to a substantial improvement in this important area”, added Nicholas Turner, M.D., Ph.D. and study co-author.

The press release ends with a note from Mace Rothenberg, M.D., chief development officer for the Oncological section at Pfizer Global Product Development: “Looking at the data from the PALOMA-3 trial and across the PALOMA program, IBRANCE has transformed the treatment landscape for this disease”.

Support The Cure For Cancer.com by shopping through our Amazon Affiliate link.

What do you think about this article? Leave your thoughts below:

Our mission is to provide hope for those who have cancer and their loved ones through the use of insight, understanding, and knowledge. Our in-depth repository of up-to-date news, data, and research.

Categories

Copyright © 2020. All Rights Reserved The Cure for Cancer

Receive your FREE eBook on 'Latest Cancer Research Articles' over email TODAY!
We would like to send you cancer relevant emails occasionally! Thanks